AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteKU14R is an antagonist of the pancreatic ??-cell atypical imidazoline binding site (putative I3 receptor). KU14R has also been shown to selectively block efaroxan-induced insulin secretion.
More Information Supplier PageKW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
More Information Supplier PageKW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
More Information Supplier PageKW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
More Information Supplier PageKW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
More Information Supplier PageKW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
More Information Supplier PageKW-2478 is an agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity.
More Information Supplier PageKW-2478 is an agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity.
More Information Supplier PageKW-2478 is an agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity.
More Information Supplier PageKW-2478 is an agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity.
More Information Supplier PageKW-2478 is an agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity.
More Information Supplier PageKX1-004 is a potent small molecule inhibitor of Src-PTK as a potential protective drug for NIHL.
More Information Supplier PageKX1-004 is a potent small molecule inhibitor of Src-PTK as a potential protective drug for NIHL.
More Information Supplier PageKX1-004 is a potent small molecule inhibitor of Src-PTK as a potential protective drug for NIHL.
More Information Supplier PageKX2-391 is a novel non-ATP competitive substrate-pocket directed SRC inhibitor.
More Information Supplier PageKX2-391 is a novel non-ATP competitive substrate-pocket directed SRC inhibitor.
More Information Supplier PageKX2-391 is a novel non-ATP competitive substrate-pocket directed SRC inhibitor.
More Information Supplier PageKX2-391 is a novel non-ATP competitive substrate-pocket directed SRC inhibitor.
More Information Supplier PageKX2-391 is a novel non-ATP competitive substrate-pocket directed SRC inhibitor.
More Information Supplier PageKX2-391 2Hcl is the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
More Information Supplier PageKX2-391 2Hcl is the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
More Information Supplier PageKX2-391 2Hcl is the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
More Information Supplier PageKY02111 is a potent and selective Wnt signaling pathway inhibitor discovered by a cell-based screening, which promotes differentiation of hESCs/iPSCs to cardiomyocytes when used at the second stage of differenitation.
More Information Supplier PageKY02111 is a potent and selective Wnt signaling pathway inhibitor discovered by a cell-based screening, which promotes differentiation of hESCs/iPSCs to cardiomyocytes when used at the second stage of differenitation.
More Information Supplier PageKY02111 is a potent and selective Wnt signaling pathway inhibitor discovered by a cell-based screening, which promotes differentiation of hESCs/iPSCs to cardiomyocytes when used at the second stage of differenitation.
More Information Supplier PageKY02111 is a potent and selective Wnt signaling pathway inhibitor discovered by a cell-based screening, which promotes differentiation of hESCs/iPSCs to cardiomyocytes when used at the second stage of differenitation.
More Information Supplier PageKY02111 is a potent and selective Wnt signaling pathway inhibitor discovered by a cell-based screening, which promotes differentiation of hESCs/iPSCs to cardiomyocytes when used at the second stage of differenitation.
More Information Supplier PageL006235 is a potent, reversible cathepsin K inhibitor (IC50 = 0.25 nM) that displays > 4000-fold selectivity over cathepsins B, L and S.
More Information Supplier PageL006235 is a potent, reversible cathepsin K inhibitor (IC50 = 0.25 nM) that displays > 4000-fold selectivity over cathepsins B, L and S.
More Information Supplier PageL-165,041 is a potent PPAR?? agonist (Ki = 6 nM); displays > 100-fold selectivity for both mouse and human PPAR?? receptors over other subtypes.
More Information Supplier PageL-165,041 is a potent PPAR?? agonist (Ki = 6 nM); displays > 100-fold selectivity for both mouse and human PPAR?? receptors over other subtypes.
More Information Supplier PageL-165,041 is a potent PPAR?? agonist (Ki = 6 nM); displays > 100-fold selectivity for both mouse and human PPAR?? receptors over other subtypes.
More Information Supplier PageL-165,041 is a potent PPAR?? agonist (Ki = 6 nM); displays > 100-fold selectivity for both mouse and human PPAR?? receptors over other subtypes.
More Information Supplier PageL-701324 is an orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor,
More Information Supplier PageL-701324 is an orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor,
More Information Supplier PageL-701324 is an orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor,
More Information Supplier PageL-741626 is a potent and selective antagonist for the dopamine receptor D2. It has good selectivity over the related D3 and D4 subtypes and other receptors.
More Information Supplier PageL-741626 is a potent and selective antagonist for the dopamine receptor D2. It has good selectivity over the related D3 and D4 subtypes and other receptors.
More Information Supplier PageL-741626 is a potent and selective antagonist for the dopamine receptor D2. It has good selectivity over the related D3 and D4 subtypes and other receptors.
More Information Supplier PageL-778123 HCl is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and 98 nM in enzyme inhibition determination.
More Information Supplier PageL-778123 HCl is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and 98 nM in enzyme inhibition determination.
More Information Supplier PageL-778123 HCl is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and 98 nM in enzyme inhibition determination.
More Information Supplier PageL-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
More Information Supplier PageL-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
More Information Supplier PageL-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
More Information Supplier PageL-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
More Information Supplier PageL-Ascorbyl 6-palmitate (Ascorbyl palmitate) is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C.
More Information Supplier PageL-Ascorbyl 6-palmitate (Ascorbyl palmitate) is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C.
More Information Supplier PageL-Ascorbyl 6-palmitate (Ascorbyl palmitate) is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C.
More Information Supplier PageL-Ascorbyl 6-palmitate (Ascorbyl palmitate) is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C.
More Information Supplier Page
